Jill Walker

3.8k total citations
58 papers, 1.7k citations indexed

About

Jill Walker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jill Walker has authored 58 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Jill Walker's work include Cancer Immunotherapy and Biomarkers (39 papers), Cancer Genomics and Diagnostics (21 papers) and Lung Cancer Treatments and Mutations (20 papers). Jill Walker is often cited by papers focused on Cancer Immunotherapy and Biomarkers (39 papers), Cancer Genomics and Diagnostics (21 papers) and Lung Cancer Treatments and Mutations (20 papers). Jill Walker collaborates with scholars based in United Kingdom, United States and Spain. Jill Walker's co-authors include Craig Barker, Anita Midha, Marlon C. Rebelatto, M. Ratcliffe, Marietta Scott, Paul Scorer, Simon Dearden, Alan Sharpe, Gael McWalter and Tsveta Milenkova and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jill Walker

54 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jill Walker United Kingdom	19	1.3k	945	590	326	238	58	1.7k
Georgy M. Manikhas Russia	11	1.4k 1.1×	1.1k 1.1×	238 0.4×	608 1.9×	143 0.6×	35	2.0k
Priyanka Shivdasani United States	9	661 0.5×	664 0.7×	357 0.6×	412 1.3×	253 1.1×	11	1.4k
Luiz H. Araujo Brazil	13	845 0.7×	597 0.6×	391 0.7×	446 1.4×	124 0.5×	69	1.4k
James Suh United States	21	1.0k 0.8×	820 0.9×	577 1.0×	519 1.6×	331 1.4×	72	1.9k
Caicun Zhou China	25	1.4k 1.1×	1.3k 1.4×	360 0.6×	389 1.2×	103 0.4×	39	2.0k
Jianchun Duan China	23	1.0k 0.8×	1.1k 1.1×	673 1.1×	511 1.6×	86 0.4×	96	1.7k
Hongnan Mo China	17	1.0k 0.8×	427 0.5×	341 0.6×	372 1.1×	223 0.9×	54	1.5k
Felice Mucilli Italy	16	1.1k 0.9×	1.5k 1.6×	464 0.8×	756 2.3×	183 0.8×	59	2.0k
Etienne Giroux‐Leprieur France	23	1.0k 0.8×	706 0.7×	252 0.4×	492 1.5×	99 0.4×	77	1.5k
Shugeng Gao China	21	529 0.4×	783 0.8×	447 0.8×	507 1.6×	289 1.2×	99	1.5k

Countries citing papers authored by Jill Walker

Since Specialization

Citations

This map shows the geographic impact of Jill Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Walker more than expected).

Fields of papers citing papers by Jill Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Walker. The network helps show where Jill Walker may publish in the future.

Co-authorship network of co-authors of Jill Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Walker. A scholar is included among the top collaborators of Jill Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Walker. Jill Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCoon, Patricia, Ying Wang, Zhongwu Lai, et al.. (2025). Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes. Clinical Cancer Research. 31(10). 1931–1942. 1 indexed citations

Joshi, Shilpy, Johannes Freudenberg, Jagdeep Singh, et al.. (2025). Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis. Digestive and Liver Disease. 57. S27–S27. 2 indexed citations

Seiwert, Tanguy Y., Sophie Wildsmith, Jérôme Fayette, et al.. (2024). Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Immunology Immunotherapy. 73(4). 70–70. 6 indexed citations

Hong, Tae Hee, Soohyun Hwang, Chris Abbosh, et al.. (2024). PP01.82 Tumor-Naïve Pre-Surgical ctDNA Detection is Prognostic in Stage I Lung Adenocarcinoma (LUAD), Associating with PD-L1 Positivity and High-Grade Histological Subtype. Journal of Thoracic Oncology. 19(7). e37–e37.

Munugalavadla, Veerendra, Aleksandra Markovets, Qin‐Wen Liu, et al.. (2023). Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies. Cancer Research. 83(7_Supplement). 3369–3369. 2 indexed citations

Wildsmith, Sophie, Jiabu Ye, Giovanni Melillo, et al.. (2022). Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. Cancer Research Communications. 2(1). 39–48. 7 indexed citations

Zając, M, Jiabu Ye, Pralay Mukhopadhyay, et al.. (2020). Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE. 15(4). e0231936–e0231936. 16 indexed citations

Schabath, Matthew B., Tapashi Dalvi, Hongyue Dai, et al.. (2019). <p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>. Cancer Management and Research. Volume 11. 9469–9481. 1 indexed citations

Zając, M, Marietta Scott, M. Ratcliffe, et al.. (2019). Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagnostic Pathology. 14(1). 99–99. 38 indexed citations

10.

Scott, Marietta, M. Ratcliffe, Catherine Wadsworth, et al.. (2018). MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples. Journal of Thoracic Oncology. 13(10). S422–S422.

11.

Scott, Marietta, Sophie Wildsmith, M. Ratcliffe, et al.. (2018). Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 29. viii375–viii375. 9 indexed citations

12.

Ratcliffe, M., Alan Sharpe, Anita Midha, et al.. (2017). Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(14). 3585–3591. 237 indexed citations

13.

Schabath, Matthew B., Tapashi Dalvi, Hongyue Dai, et al.. (2017). P1.01-042 Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S475–S476. 1 indexed citations

14.

Stokes, Michael E., Sophie Wildsmith, Maria Secrier, et al.. (2017). Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts). Annals of Oncology. 28. v375–v375. 5 indexed citations

15.

Rebelatto, Marlon C., Anita Midha, Amita Mistry, et al.. (2016). Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology. 11(1). 95–95. 135 indexed citations

16.

Patani, Neill, Anita K. Dunbier, H Anderson, et al.. (2014). Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. Clinical Cancer Research. 20(15). 3962–3973. 16 indexed citations

17.

Douillard, Jean‐Yves, Gyula Ostoros, Manuel Cobo, et al.. (2014). Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology. 9(9). 1345–1353. 348 indexed citations

18.

Walker, Jill, et al.. (2012). Antenatal screening: an on line learning tool.. PubMed. 108(27). 22–3. 1 indexed citations

19.

Rajeshkumar, N.V., Aik Choon Tan, Elizabeth De Oliveira, et al.. (2009). Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. Clinical Cancer Research. 15(12). 4138–4146. 75 indexed citations

20.

Heek, N. Tjarda van, Patrick Sturm, Jill Walker, et al.. (2005). Comparison of the novel quantitative ARMS assay and an enriched PCR–ASO assay for K- ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. Journal of Clinical Pathology. 58(12). 1315–1320. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact